Literature DB >> 7633875

Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin.

P P Choudhary1, R A Hughes.   

Abstract

To assess long-term treatment of chronic idiopathic demyelinating polyradiculoneuropathy (CIDP) with plasma exchange (PE) and intravenous immunoglobulin (IVIg), we studied 105 patients retrospectively by case-notes and follow-up. Thirty-three were treated with PE; 23 responded well. Twenty-two were treated with IVIg; 14 responded well and one had a hypotensive reaction during the first infusion. For both treatments, responders were more likely to be female and younger, and to have a shorter duration of symptoms. Most patients required only one course of treatment. Seven patients received repeated courses of PE for 8.1-59.7 months; seven received repeated courses of IVIg for 6-51 months. Transient complications occurred with PE: hypotension in three, difficulty in gaining venous access in three, and haematoma, bleeding diathesis, hypocalcaemia, and septicaemia in one patient each. Four patients transferred from long-term PE to IVIg, but the fifth responded to PE only. Two patients who were transferred from PE to IVIg were eventually able to stop all treatments. Long-term use of IVIg was free of any significant complications. Both PE and IVIg are possible long-term treatments for CIDP, but both are expensive, and PE had more side-effects.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7633875

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  11 in total

1.  Chronic Inflammatory Demyelinating Polyneuropathy.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-07       Impact factor: 3.598

Review 2.  Management of chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Richard A C Hughes
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Early predictive factors of disability in CIDP.

Authors:  Emanuele Spina; Antonietta Topa; Rosa Iodice; Stefano Tozza; Lucia Ruggiero; Raffaele Dubbioso; Marcello Esposito; Dario Bruzzese; Lucio Santoro; Fiore Manganelli
Journal:  J Neurol       Date:  2017-08-02       Impact factor: 4.849

4.  Two years' long-term follow up in chronic inflammatory demyelinating polyradiculoneuropathy: efficacy of intravenous immunoglobulin treatment.

Authors:  Gisa Ellrichmann; Ralf Gold; Ilya Ayzenberg; Min-Suk Yoon; Christiane Schneider-Gold
Journal:  Ther Adv Neurol Disord       Date:  2016-12-09       Impact factor: 6.570

5.  An update on the management of chronic inflammatory demyelinating polyneuropathy.

Authors:  Kenneth C Gorson
Journal:  Ther Adv Neurol Disord       Date:  2012-11       Impact factor: 6.570

6.  Chronic inflammatory demyelinating polyradiculoneuropathy: in a remote northern Ontario hospital.

Authors:  Taryn Taylor
Journal:  Can Fam Physician       Date:  2013-04       Impact factor: 3.275

Review 7.  Inflammatory demyelinating neuropathies and neuropathies associated with monoclonal gammopathies: treatment update.

Authors:  Andreas J Steck; Adam Czaplinski; Susanne Renaud
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

Review 8.  Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Man Mohan Mehndiratta; Richard A C Hughes; Jane Pritchard
Journal:  Cochrane Database Syst Rev       Date:  2015-08-25

Review 9.  Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies.

Authors:  Melvin Berger; Daniel E McCallus; Cindy Shin-Yi Lin
Journal:  J Peripher Nerv Syst       Date:  2013-12       Impact factor: 3.494

Review 10.  Treatment of chronic inflammatory demyelinating polyneuropathy: from molecular bases to practical considerations.

Authors:  Paolo Ripellino; Thomas Fleetwood; Roberto Cantello; Cristoforo Comi
Journal:  Autoimmune Dis       Date:  2014-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.